A randomized controlled trial for the Bu-Xue Yi-Mu particles in the treatment of postpartum disease

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Subjects' informed consent to participate voluntarily, and signed informed consent in person or by legal guardian;
•2. Aged 20-40 years;
•3. Maternity or cesarean delivery: 37 weeks-41 weeks + 6 days;
•4. Hemoglobin is greater than 90 g/L and less than 105 g/L.

•1. Patients with severe medical comorbidities (heart disease, liver disease, kidney disease, etc.) have abnormal liver and kidney function; or the value of alanine aminotransferase (ALT) or or aspartate aminotransferase (AST) >2 ULN;
•Those: or those whose creatinine (Cr) is greater than the upper limit of normal value;
•2. People with severe endocrine diseases (pre-pregnancy diabetes, hyperthyroidism, etc.);
•3. those with pregnancy-induced hypertension and sepsis;
•4. Reproductive tract malformations and uterine infections;
•5. Placenta implantation or dangerous placenta previa;
•6. Those who have failed the trial and transferred to cesarean section;
•7. >=2 abdominal operations related to the uterus and >=4 deliveries;
•8. those with severe coagulopathy or whose PT and or APTT values ??exceed the upper limit of normal values; or
•Those with platelets less than 80x10^9/L;
•9. Uterine fibroids: single fibroids >=5cm; or multiple fibroids> 3, single fibroids >=2cm;
•10. Those with a history of adenomyoma before pregnancy;
•11. Multiple pregnancy;
•12. Subjects who are taking HIV protease inhibitors;
•13. Those who are allergic to the test drug;
•14. Participated in other clinical researchers within three months before enrollment;
•15. Researchers do not consider it appropriate to participate in this trial.

发起方

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology